Ireland-based Mallinckrodt Public Limited Company focuses on developing treatments for autoimmune and rare diseases (including neurology, rheumatology, nephrology and pulmonology) as well as therapies for pain management.
The company develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals. The company reports in three segments: Specialty Brands, Specialty Generics and Nuclear Imaging. The company sold its contrast media and delivery systems business to Guerbet S.A. in Nov 2015.
Mallinckrodt acquired Ikaria Inc. in 2015 to strengthen its business in the hospital market. With the addition of Inomax to its portfolio, Mallinckrodt gained access to the market for neonatal critical care, which helped it to diversify its portfolio in the Specialty Brands segment. The company also acquired Therakos Inc. in Sep 2015 to widen its presence from multimodal surgical pain management and critical care respiratory therapies in neonatal intensive care units to include innovative immunotherapy therapies. Moreover, in Feb 2016 the company acquired three commercial stage topical hemostasis drugs from The Medicines Company to strengthen its growing hospital portfolio.
However, the company sold its Nuclear Imaging business to IBA Molecular for $690 million.
Mallinckrodt has an excellent earnings track record with the company delivering positive earnings surprises in each of the last four quarters with a positive average earnings surprise of 11.20%. Estimate revisions for Mallinckrodt for fiscal 2017 have were up by three cents in the last thirty days.
Currently, Mallinckrodt has a Zacks Rank #5(Strong Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mallinckrodt beat on earnings. Our consensus called for EPS of $1.84, and the company reported EPS of $1.91.
Revenue: Revenues also surpassed expectations. Mallinckrodt posted revenues of $829.9 million, compared to our consensus estimate of $824.8 million.
Key Stats: Revenue growth was primarily driven by volume growth of key branded drugs – Acthar, Inomax, and Ofirmev. However, sales of Therakos were down. Specialty generics segment continue to be under pressure.
Share Price Impact: Shares rose more than 0.3% in pre-market trading.
Check back later for our full write up on this Mallinckrodt earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Image: Bigstock
Mallinckrodt (MNK) Tops Earnings & Sales Estimates
Ireland-based Mallinckrodt Public Limited Company focuses on developing treatments for autoimmune and rare diseases (including neurology, rheumatology, nephrology and pulmonology) as well as therapies for pain management.
The company develops, manufactures, markets and distributes both branded and specialty generic pharmaceuticals. The company reports in three segments: Specialty Brands, Specialty Generics and Nuclear Imaging. The company sold its contrast media and delivery systems business to Guerbet S.A. in Nov 2015.
Mallinckrodt acquired Ikaria Inc. in 2015 to strengthen its business in the hospital market. With the addition of Inomax to its portfolio, Mallinckrodt gained access to the market for neonatal critical care, which helped it to diversify its portfolio in the Specialty Brands segment. The company also acquired Therakos Inc. in Sep 2015 to widen its presence from multimodal surgical pain management and critical care respiratory therapies in neonatal intensive care units to include innovative immunotherapy therapies. Moreover, in Feb 2016 the company acquired three commercial stage topical hemostasis drugs from The Medicines Company to strengthen its growing hospital portfolio.
However, the company sold its Nuclear Imaging business to IBA Molecular for $690 million.
Mallinckrodt has an excellent earnings track record with the company delivering positive earnings surprises in each of the last four quarters with a positive average earnings surprise of 11.20%. Estimate revisions for Mallinckrodt for fiscal 2017 have were up by three cents in the last thirty days.
Mallinckrodt PLC Price and EPS Surprise
Mallinckrodt PLC Price and EPS Surprise | Mallinckrodt PLC Quote
Currently, Mallinckrodt has a Zacks Rank #5(Strong Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Mallinckrodt beat on earnings. Our consensus called for EPS of $1.84, and the company reported EPS of $1.91.
Revenue: Revenues also surpassed expectations. Mallinckrodt posted revenues of $829.9 million, compared to our consensus estimate of $824.8 million.
Key Stats: Revenue growth was primarily driven by volume growth of key branded drugs – Acthar, Inomax, and Ofirmev. However, sales of Therakos were down. Specialty generics segment continue to be under pressure.
Share Price Impact: Shares rose more than 0.3% in pre-market trading.
Check back later for our full write up on this Mallinckrodt earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>